Interní Med. 2004; 6(2): 64-69

Kardiovaskulární riziko metabolického syndromu a možnosti jeho léčebného ovlivnění

MUDr. Otto Mayer jr., CSc

Keywords: metabolic syndrome, risk factors, cardiovascular diseases, dignosis, treatment.

Published: December 31, 2004  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mayer O, CSc. Kardiovaskulární riziko metabolického syndromu a možnosti jeho léčebného ovlivnění. Interní Med. 2004;6(2):64-69.

MUDr. Otto Mayer jr., CSc.

Centrum preventivní kardiologie, II. Interní klinika LFUK a FN Plzeň

Metabolický syndrom představuje obzvláště nebezpečné seskupení několika kardiovaskulárních rizikových faktorů, pokrývajících v celé šíři etiologií vaskulárních chorob. Mezi nejčastější rizikové faktory patří inzulinorezistence s různým stupněm intolerance glukózy, typická dyslipidemie, hypertenze, hyperkoagulační stav a abdominální obezita. Vzhledem k vysokému riziku kardiovaskulární příhody či přechodu do manifestního diabetu, by pacienti s metabolickým syndromem měli být aktivně vyhledáváni a stát se pak cílem obzvláště intenzivních preventivních a terapeutických opatření.

Cardiovascular risk of metabolic syndrome and the treatment possibilities

Metabolic syndrome represents an extremely dangerous cluster of cardiovascular risk factor, covering in the whole the etiology of vascular diseases. The most common risk factors are insulin resistance with various degree of glucose, typical dyslipidemia, hypercoagulation status and abdominal obesity. Because of high risk of vascular event or new onset of diabetes, patients with metabolic syndrome should be screened and intensively treated.

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991; 87: 2246-2252. Go to original source... Go to PubMed...
    2. Austin MA, Breslow JH, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1996; 260: 1917-1921. Go to original source...
    3. Azen SP, Peters RK, Berkowitz K, Kjos S, Xiang A, Buchanan TA. TRIPOD (TRoglitazone in the Prevention of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 1998; 19: 217-231. Go to original source... Go to PubMed...
    4. Balkau B, Charles MA. Comments on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance. Diabetic Medicine 1999; 16: 442-443. Go to original source... Go to PubMed...
    5. Baron AD. Vascular reactivity. Am J Cardiol 1999; 84 (suppl.): 25J-27J. Go to original source... Go to PubMed...
    6. Belalcazar LM, Ballantyne CM. Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol. Prog Cardiovasc Dis 1998; 41: 151-174. Go to original source... Go to PubMed...
    7. Berne C, Fagius J, Pollare T, Hjemdahl P. The sympathetic response to euglycaemic hyperinsulinaemia: evidence from micro-electrode nerve recordings in healthy subjects. Diabetologia. 1992; 35: 873-879. Go to original source... Go to PubMed...
    8. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP-NIDDM Trial: an international study on the efficacy of an -glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care 1998; 21: 1720-1725. Go to original source... Go to PubMed...
    9. Collins R, Peto R, Armitage J. The MRC/BHF Heart Protection Study: preliminary results. Int J Clin Pract 2002; 56: 53-56. Go to original source...
    10. Defronzo RA, Cooke CR, Andres R, et al. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest 1975; 55: 845-855. Go to original source... Go to PubMed...
    11. DeFronzo RA, Ferrannini E, Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194. Go to original source... Go to PubMed...
    12. Diabetes Prevention Program Research Group, Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393-403. Go to original source... Go to PubMed...
    13. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS: Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622. Go to original source... Go to PubMed...
    14. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Annals of Internal Medicine 1993; 118: 956-963. Go to original source... Go to PubMed...
    15. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47. Go to original source... Go to PubMed...
    16. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults. Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359. Go to original source... Go to PubMed...
    17. Groop and M. Orho-Melander, The dysmetabolic syndrome. Journal of Internal Medicine 2001; 250: 105-120. Go to original source... Go to PubMed...
    18. Haenni A, Lithell H. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives. J Hypertens. 1999; (Suppl 3): S29-35.
    19. Haffner SM, Mykkänen L, Robbins D, Valdez R, Miettinen H, Howard BV, Stern MP, Bowsher R. A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects. Diabetologia 1995; 38: 1328-1336. Go to original source... Go to PubMed...
    20. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.